

C2

conjugated to a lymphokine or other effector molecule which stimulates an immune response.

IN THE SPECIFICATION

(1) On pages 1 and 63, delete the title and substitute the following title:

✓ “Cell Compositions Comprising Molecular Complexes That Modify Immune Responses.”

(2) On page 63, delete the abstract and substitute the following abstract:

C3
Compositions comprising a cell in which a molecular complex with high affinity for its cognate ligand is bound to the surface of the cell are provided. To form the molecular complexes, extracellular domains of transmembrane heterodimeric proteins, particularly T cell receptor and major histocompatibility complex proteins, can be covalently linked to the heavy and light chains of immunoglobulin molecules. The molecular complexes can be used, *inter alia*, to detect and regulate antigen-specific T cells and as therapeutic agents for treating disorders involving immune system regulation, such as allergies, autoimmune diseases, tumors, infections, and transplant rejection. Optionally, identical antigenic peptides can be bound to each ligand binding site of a molecular complex.

Remarks

Applicants appreciate the Examiner's acknowledgement that the claims are free of the prior art.

The Amendments

Claim 32 has been amended to recite that “an identical antigenic peptide is bound to each ligand binding site.” This recitation is supported in the specification at page 19, lines 17-18